{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:18:26Z","timestamp":1790396306286,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T00:00:00Z","timestamp":1392076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00280-014-2402-3","type":"journal-article","created":{"date-parts":[[2014,2,10]],"date-time":"2014-02-10T18:31:28Z","timestamp":1392057088000},"page":"875-883","source":"Crossref","is-referenced-by-count":41,"title":["Asparaginase in the treatment of non-ALL hematologic malignancies"],"prefix":"10.1007","volume":"73","author":[{"given":"Ashkan","family":"Emadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Zokaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Sausville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,11]]},"reference":[{"issue":"6","key":"2402_CR1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1084\/jem.98.6.583","volume":"98","author":"JG Kidd","year":"1953","unstructured":"Kidd JG (1953) Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: discussion. J Exp Med 98(6):583\u2013606","journal-title":"J Exp Med"},{"key":"2402_CR2","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/1911114a0","volume":"191","author":"JD Broome","year":"1961","unstructured":"Broome JD (1961) Evidence that the L-asparaginase activity in guinea pig serum is responsible for antilymphoma effects. Nature 191:1114\u20131115","journal-title":"Nature"},{"issue":"3713","key":"2402_CR3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1126\/science.151.3713.998","volume":"151","author":"TO Yellin","year":"1966","unstructured":"Yellin TO, Wriston JC Jr (1966) Antagonism of purified asparaginase from guinea pig serum toward lymphoma. Science 151(3713):998\u2013999","journal-title":"Science"},{"key":"2402_CR4","doi-asserted-by":"crossref","unstructured":"Dolowy WC, Henson D, Cornet J, Sellin H (1966) Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 19(12):1813\u20131819","DOI":"10.1002\/1097-0142(196612)19:12<1813::AID-CNCR2820191208>3.0.CO;2-E"},{"issue":"7571","key":"2402_CR5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(68)90977-X","volume":"2","author":"HE Wade","year":"1968","unstructured":"Wade HE, Elsworth R, Herbert D, Keppie J, Sargeant K (1968) A new L-asparaginase with antitumour activity? Lancet 2(7571):776\u2013777","journal-title":"Lancet"},{"key":"2402_CR6","doi-asserted-by":"crossref","unstructured":"Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH (2011)\u00a0L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117(2):238\u2013249","DOI":"10.1002\/cncr.25489"},{"key":"2402_CR7","doi-asserted-by":"crossref","unstructured":"Dhavala P, Papageorgiou AC (2009)\u00a0Structure of Helicobacter pylori L-asparaginase at 1.4 \u00c5 resolution. Acta Crystallogr D Biol Crystallogr 65(Pt 12):1253\u20131261","DOI":"10.1107\/S0907444909038244"},{"issue":"11","key":"2402_CR8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1139\/o72-157","volume":"50","author":"E Soru","year":"1972","unstructured":"Soru E, Teodorescu M, Zaharia O, Szabados J, Rudescu K (1972) L-Asparaginase from the BCG strain of Mycobacterium bovis. I. Purification and in vitro immunosuppressive properties. Can J Biochem 50(11):1149\u20131157","journal-title":"Can J Biochem"},{"issue":"6","key":"2402_CR9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1128\/AEM.23.6.1163-1164.1972","volume":"23","author":"PJ DeJong","year":"1972","unstructured":"DeJong PJ (1972) L-Asparaginase production by Streptomyces griseus. Appl Microbiol 23(6):1163\u20131164","journal-title":"Appl Microbiol"},{"key":"2402_CR10","first-page":"146","volume":"327","author":"P Jones","year":"1973","unstructured":"Jones P, Kristiansen T, Einarsson M (1973) Purification and properties of L-asparaginase from Acinetobacter calcoaceticus. Biochem Biophys Acta 327:146","journal-title":"Biochem Biophys Acta"},{"issue":"16","key":"2402_CR11","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1016\/S0021-9258(19)41055-7","volume":"250","author":"B Lee","year":"1975","unstructured":"Lee B, Yang HJ, Henry GM, Seymour JP, Chibata I (1975) Crystallographic studies on L-asparaginase from Proteus vulgaris. II. Symmetry and location of the tetrameric molecule. J Biol Chem 250(16):6228\u20136231","journal-title":"J Biol Chem"},{"issue":"1","key":"2402_CR12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0005-2795(74)90266-9","volume":"365","author":"HA Whelan","year":"1974","unstructured":"Whelan HA, Wriston JC Jr (1974) Purification and properties of L-asparaginase from Serratia marcescens. Biochim Biophys Acta 365(1):212\u2013222","journal-title":"Biochim Biophys Acta"},{"key":"2402_CR13","doi-asserted-by":"crossref","unstructured":"Abuchowski A, Kafkewitz D, Davis FF (1979) A rapid purification procedure for L-asparaginase from Vibrio succinogenes. Prep Biochem 9(3):205\u2013211","DOI":"10.1080\/00327487908061685"},{"key":"2402_CR14","doi-asserted-by":"crossref","unstructured":"Kavitha A, Vijayalakshmi M (2012) A study on L-asparaginase of Nocardia levis MK-VL_113. Sci World J. 2012:160434","DOI":"10.1100\/2012\/160434"},{"issue":"1","key":"2402_CR15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1432-1033.1996.0201t.x","volume":"241","author":"J Lubkowski","year":"1996","unstructured":"Lubkowski J, Palm GJ, Gilliland GL, Derst C, Rohm KH, Wlodawer A (1996) Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase. Eur J Biochem 241(1):201\u2013207","journal-title":"Eur J Biochem"},{"issue":"34","key":"2402_CR16","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/bi00200a005","volume":"33","author":"J Lubkowski","year":"1994","unstructured":"Lubkowski J, Wlodawer A, Ammon HL, Copeland TD, Swain AL (1994) Structural characterization of pseudomonas 7A glutaminase-asparaginase. Biochemistry 33(34):10257\u201310265","journal-title":"Biochemistry"},{"issue":"6","key":"2402_CR17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1021\/bi991797d","volume":"39","author":"E Ortlund","year":"2000","unstructured":"Ortlund E, Lacount MW, Lewinski K, Lebioda L (2000) Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu. Biochemistry 39(6):1199\u20131204","journal-title":"Biochemistry"},{"issue":"3","key":"2402_CR18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","volume":"13","author":"MD Amylon","year":"1999","unstructured":"Amylon MD, Shuster J, Pullen J et al (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13(3):335\u2013342","journal-title":"Leukemia"},{"key":"2402_CR19","unstructured":"FDA Label for Asparaginase: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/101063s5169lbl.pdf"},{"key":"2402_CR20","unstructured":"FDA Label for Erwinaze: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125359lbl.pdf"},{"issue":"2","key":"2402_CR21","first-page":"175","volume":"7","author":"A Abuchowski","year":"1984","unstructured":"Abuchowski A, Kazo GM, Verhoest CR Jr et al (1984) Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 7(2):175\u2013186","journal-title":"Cancer Biochem Biophys"},{"issue":"6","key":"2402_CR22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","volume":"74","author":"RL Capizzi","year":"1971","unstructured":"Capizzi RL, Bertino JR, Skeel RT et al (1971) L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 74(6):893\u2013901","journal-title":"Ann Intern Med"},{"issue":"2","key":"2402_CR23","first-page":"466","volume":"30","author":"DH Ho","year":"1970","unstructured":"Ho DH, Whitecar JP Jr, Luce JK, Frei E 3rd (1970) L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res 30(2):466\u2013472","journal-title":"Cancer Res"},{"issue":"2","key":"2402_CR24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-3565(25)32435-3","volume":"216","author":"Y Kamisaki","year":"1981","unstructured":"Kamisaki Y, Wada H, Yagura T, Matsushima A, Inada Y (1981) Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 216(2):410\u2013414","journal-title":"J Pharmacol Exp Ther"},{"key":"2402_CR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1749-6632.1990.tb18151.x","volume":"613","author":"H Wada","year":"1990","unstructured":"Wada H, Imamura I, Sako M et al (1990) Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann N Y Acad Sci 613:95\u2013108","journal-title":"Ann N Y Acad Sci"},{"key":"2402_CR26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF03259345","volume":"5","author":"S Patel","year":"1996","unstructured":"Patel S, Benfield P (1996) Pegasparaginase (polyethylene glycol L-asparaginase). Clin Immunother 5:492\u2013496","journal-title":"Clin Immunother"},{"issue":"5","key":"2402_CR27","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","volume":"75","author":"LJ Ettinger","year":"1995","unstructured":"Ettinger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL (1995) An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 75(5):1176\u20131181","journal-title":"Cancer"},{"key":"2402_CR28","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1016\/S0021-9258(18)95875-8","volume":"247","author":"H Cedar","year":"1967","unstructured":"Cedar H, Schwartz JH (1967) Localization of the two asparaginases in anaerobically grown E. coli. J Biol Chem 247:3753\u20133755","journal-title":"J Biol Chem"},{"issue":"1","key":"2402_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157489212798358001","volume":"7","author":"D Covini","year":"2012","unstructured":"Covini D, Tardito S, Bussolati O et al (2012) Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat Anticancer Drug Discov 7(1):4\u201313","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"5","key":"2402_CR30","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1073\/pnas.56.5.1516","volume":"56","author":"JH Schwartz","year":"1966","unstructured":"Schwartz JH, Reeves JY, Broome JD (1966) Two L-asparaginases from E. coli and their action against tumors. Proc Natl Acad Sci USA. 56(5):1516\u20131519","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"2402_CR31","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/JB.96.6.2043-2048.1968","volume":"96","author":"H Cedar","year":"1968","unstructured":"Cedar H, Schwartz JH (1968) Production of L-asparaginase II by Escherichia coli. J Bacteriol 96(6):2043\u20132048","journal-title":"J Bacteriol"},{"issue":"1","key":"2402_CR32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/JB.118.1.231-241.1974","volume":"118","author":"RC Willis","year":"1974","unstructured":"Willis RC, Woolfolk CA (1974) Asparagine utilization in Escherichia coli. J Bacteriol 118(1):231\u2013241","journal-title":"J Bacteriol"},{"key":"2402_CR33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1128\/JB.154.1.513-515.1983","volume":"154","author":"TD Casale","year":"1983","unstructured":"Casale TD, Sollitti P, Chesney RH (1983) Cytoplasmic L-asparaginase: isolation of a defective strain and mapping of ans A. J Bacteriol 154:513\u2013515","journal-title":"J Bacteriol"},{"issue":"3","key":"2402_CR34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/jb.172.3.1491-1498.1990","volume":"172","author":"MP Jennings","year":"1990","unstructured":"Jennings MP, Beacham IR (1990) Analysis of the Escherichia coli gene encoding L-asparaginase II, ansB, and its regulation by cyclic AMP receptor and FNR proteins. J Bacteriol 172(3):1491\u20131498","journal-title":"J Bacteriol"},{"issue":"3","key":"2402_CR35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1999.17.3.818","volume":"17","author":"CH Pui","year":"1999","unstructured":"Pui CH, Boyett JM, Relling MV et al (1999) Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 17(3):818\u2013824","journal-title":"J Clin Oncol"},{"issue":"10","key":"2402_CR36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(01)00516-2","volume":"2","author":"CH Pui","year":"2001","unstructured":"Pui CH, Campana D, Evans WE (2001) Childhood acute lymphoblastic leukaemia\u2014current status and future perspectives. Lancet Oncol 2(10):597\u2013607","journal-title":"Lancet Oncol"},{"issue":"4","key":"2402_CR37","first-page":"294","volume":"3","author":"Y Kiriyama","year":"1989","unstructured":"Kiriyama Y, Kubota M, Takimoto T et al (1989) Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia 3(4):294\u2013297","journal-title":"Leukemia"},{"issue":"1","key":"2402_CR38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0006-291X(68)90028-4","volume":"31","author":"MD Prager","year":"1968","unstructured":"Prager MD, Bachynsky N (1968) Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas. Biochem Biophys Res Commun 31(1):43\u201347","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2402_CR39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"VI Avramis","year":"2005","unstructured":"Avramis VI, Panosyan EH (2005) Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44(4):367\u2013393","journal-title":"Clin Pharmacokinet"},{"issue":"2C","key":"2402_CR40","first-page":"1121","volume":"24","author":"EH Panosyan","year":"2004","unstructured":"Panosyan EH, Grigoryan RS, Avramis IA et al (2004) Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer research 24(2C):1121\u20131125","journal-title":"Anticancer research"},{"issue":"6","key":"2402_CR41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00000658-199312000-00004","volume":"218","author":"WW Souba","year":"1993","unstructured":"Souba WW (1993) Glutamine and cancer. Ann Surg 218(6):715\u2013728","journal-title":"Ann Surg"},{"issue":"4","key":"2402_CR42","first-page":"929","volume":"30","author":"DA Cooney","year":"1970","unstructured":"Cooney DA, Capizzi RL, Handschumacher RE (1970) Evaluation of l-asparagine metabolism in animals and man. Cancer Res 30(4):929\u2013935","journal-title":"Cancer Res"},{"issue":"1","key":"2402_CR43","first-page":"78","volume":"40","author":"SR Mardashev","year":"1975","unstructured":"Mardashev SR, Nikolaev A, Kozlov EA, Petrii OP (1975) Purification of microbial asparaginases by the aid of affinity chromatography. Biokhimiia 40(1):78\u201382","journal-title":"Biokhimiia"},{"issue":"6","key":"2402_CR44","first-page":"391","volume":"43","author":"VP Kamble","year":"2006","unstructured":"Kamble VP, Rao RS, Borkar PS, Khobragade CN, Dawane BS (2006) Purification of L-asparaginase from a bacteria Erwinia carotovora and effect of a dihydropyrimidine derivative on some of its kinetic parameters. Indian J Biochem Biophys 43(6):391\u2013394","journal-title":"Indian J Biochem Biophys"},{"issue":"14","key":"2402_CR45","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/S0021-9258(18)62984-9","volume":"245","author":"PP Ho","year":"1970","unstructured":"Ho PP, Milikin EB, Bobbitt JL et al (1970) Crystalline L-asparaginase from Escherichia coli B. I. Purification and chemical characterization. J Biol Chem 245(14):3708\u20133715","journal-title":"J Biol Chem"},{"issue":"10","key":"2402_CR46","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1110\/ps.9.10.2009","volume":"9","author":"C Derst","year":"2000","unstructured":"Derst C, Henseling J, Rohm KH (2000) Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci 9(10):2009\u20132017","journal-title":"Protein Sci"},{"issue":"Pt 3","key":"2402_CR47","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1042\/bj3020921","volume":"302","author":"ZB Moola","year":"1994","unstructured":"Moola ZB, Scawen MD, Atkinson T, Nicholls DJ (1994) Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 302(Pt 3):921\u2013927","journal-title":"Biochem J"},{"issue":"4","key":"2402_CR48","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jbiotec.2006.07.037","volume":"127","author":"GA Kotzia","year":"2007","unstructured":"Kotzia GA, Labrou NE (2007) L-Asparaginase from Erwinia chrysanthemi 3937: cloning, expression and characterization. J Biotechnol 127(4):657\u2013669","journal-title":"J Biotechnol"},{"issue":"8","key":"2402_CR49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/MPH.0b013e31823313be","volume":"33","author":"VI Avramis","year":"2011","unstructured":"Avramis VI (2011) Asparaginases: a successful class of drugs against leukemias and lymphomas. J Pediatr Hematol Oncol 33(8):573\u2013579","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2402_CR50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/pbc.20713","volume":"47","author":"M Jarrar","year":"2006","unstructured":"Jarrar M, Gaynon PS, Periclou AP et al (2006) Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children\u2019s Oncology Group study (CCG-1941). Pediatr Blood Cancer 47(2):141\u2013146","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2402_CR51","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP et al (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood 99(6):1986\u20131994","journal-title":"Blood"},{"issue":"1","key":"2402_CR52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/0008-5472.291.65.1","volume":"65","author":"BM Fine","year":"2005","unstructured":"Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM (2005) A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res 65(1):291\u2013299","journal-title":"Cancer Res"},{"key":"2402_CR53","doi-asserted-by":"crossref","unstructured":"Shan J, Lopez MC, Baker HV, Kilberg MS (2010) Expression profiling after activation of the amino acid deprivation response in HepG2 human hepatoma cells. Physiol Genomics\u00a041(3):315\u2013327","DOI":"10.1152\/physiolgenomics.00217.2009"},{"issue":"42","key":"2402_CR54","doi-asserted-by":"crossref","first-page":"31222","DOI":"10.1074\/jbc.M604511200","volume":"281","author":"RB Reinert","year":"2006","unstructured":"Reinert RB, Oberle LM, Wek SA et al (2006) Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 281(42):31222\u201331233","journal-title":"J Biol Chem"},{"issue":"20","key":"2402_CR55","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","volume":"122","author":"L Willems","year":"2013","unstructured":"Willems L, Jacque N, Jacquel A et al (2013) Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122(20):3521\u20133532","journal-title":"Blood"},{"issue":"5","key":"2402_CR56","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood-2010-07-298422","volume":"117","author":"MN Offman","year":"2011","unstructured":"Offman MN, Krol M, Patel N et al (2011) Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 117(5):1614\u20131621","journal-title":"Blood"},{"issue":"5","key":"2402_CR57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2362.1988.tb01049.x","volume":"18","author":"G Ollenschlager","year":"1988","unstructured":"Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B (1988) Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 18(5):512\u2013516","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"2402_CR58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","volume":"26","author":"EH Panosyan","year":"2004","unstructured":"Panosyan EH, Seibel NL, Martin-Aragon S et al (2004) Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children\u2019s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 26(4):217\u2013226","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"2402_CR59","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","volume":"109","author":"D Douer","year":"2007","unstructured":"Douer D, Yampolsky H, Cohen LJ et al (2007) Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55\u00a0years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109(7):2744\u20132750","journal-title":"Blood"},{"issue":"31","key":"2402_CR60","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2009.24.8518","volume":"27","author":"CH Pui","year":"2009","unstructured":"Pui CH (2009) Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 27(31):5121\u20135123","journal-title":"J Clin Oncol"},{"issue":"2","key":"2402_CR61","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(197002)25:2<244::AID-CNCR2820250203>3.0.CO;2-V","volume":"25","author":"MK Schwartz","year":"1970","unstructured":"Schwartz MK, Lash ED, Oettgen HF, Tomato FA (1970) L-asparaginase activity in plasma and other biological fluids. Cancer 25(2):244\u2013252","journal-title":"Cancer"},{"issue":"2","key":"2402_CR62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1200\/JCO.1995.13.2.339","volume":"13","author":"SP Dibenedetto","year":"1995","unstructured":"Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C, Lo Nigro L (1995) Levels of l-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 13(2):339\u2013344","journal-title":"J Clin Oncol"},{"issue":"11 Pt 1","key":"2402_CR63","first-page":"4554","volume":"41","author":"R Riccardi","year":"1981","unstructured":"Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41(11 Pt 1):4554\u20134558","journal-title":"Cancer Res"},{"issue":"5","key":"2402_CR64","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.1999.17.5.1568","volume":"17","author":"MH Woo","year":"1999","unstructured":"Woo MH, Hak LJ, Storm MC et al (1999) Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 17(5):1568\u20131573","journal-title":"J Clin Oncol"},{"issue":"2","key":"2402_CR65","first-page":"72","volume":"21","author":"DH Ho","year":"1981","unstructured":"Ho DH, Yap HY, Brown N et al (1981) Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol 21(2):72\u201378","journal-title":"J Clin Pharmacol"},{"issue":"19","key":"2402_CR66","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJM196911062811902","volume":"281","author":"CM Haskell","year":"1969","unstructured":"Haskell CM, Canellos GP, Leventhal BG et al (1969) L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281(19):1028\u20131034","journal-title":"N Engl J Med"},{"key":"2402_CR67","first-page":"114","volume":"13","author":"J Kurtzberg","year":"1994","unstructured":"Kurtzberg J, Asselin B, Poplack D (1994) PEG L-asparaginase (PEG-ASP) pharmacology in pediatric patients with acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 13:114","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"4","key":"2402_CR68","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/1097-0142(1971)28:4<825::AID-CNCR2820280404>3.0.CO;2-H","volume":"28","author":"BG Leventhal","year":"1971","unstructured":"Leventhal BG, Henderson ES (1971) Therapy of acute leukemia with drug combinations which include asparaginase. Cancer 28(4):825\u2013829","journal-title":"Cancer"},{"issue":"Suppl","key":"2402_CR69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/10428199309149127","volume":"10","author":"RL Capizzi","year":"1993","unstructured":"Capizzi RL (1993) Asparaginase revisited. Leuk Lymphoma 10(Suppl):147\u2013150","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2402_CR70","first-page":"256","volume":"33","author":"AI Goldberg","year":"1973","unstructured":"Goldberg AI, Cooney DA, Glynn JP, Homan ER, Gaston MR, Milman HA (1973) The effects of immunization to L-asparaginase on antitumor and enzymatic activity. Cancer Res 33(2):256\u2013261","journal-title":"Cancer Res"},{"issue":"4","key":"2402_CR71","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/092986613805290426","volume":"20","author":"V Agrawal","year":"2013","unstructured":"Agrawal V, Woo J, Borthakur G, Kantarjian H, Frankel A (2013) Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 20(4):392\u2013402","journal-title":"Protein Pept Lett"},{"issue":"9","key":"2402_CR72","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","volume":"11","author":"BL Asselin","year":"1993","unstructured":"Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11(9):1780\u20131786","journal-title":"J Clin Oncol"},{"issue":"8","key":"2402_CR73","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","volume":"99","author":"M Duval","year":"2002","unstructured":"Duval M, Suciu S, Ferster A et al (2002) Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children\u2019s Leukemia Group phase 3 trial. Blood 99(8):2734\u20132739","journal-title":"Blood"},{"issue":"3","key":"2402_CR74","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B et al (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109(3):896\u2013904","journal-title":"Blood"},{"issue":"2","key":"2402_CR75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.1999.01192.x","volume":"104","author":"JP Vieira Pinheiro","year":"1999","unstructured":"Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U et al (1999) Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL\/NHL-BFM treatment protocols. Br J Haematol 104(2):313\u2013320","journal-title":"Br J Haematol"},{"issue":"9","key":"2402_CR76","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","volume":"32A","author":"J Boos","year":"1996","unstructured":"Boos J, Werber G, Ahlke E et al (1996) Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 32A(9):1544\u20131550","journal-title":"Eur J Cancer"},{"issue":"2","key":"2402_CR77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(197002)25:2<279::AID-CNCR2820250205>3.0.CO;2-7","volume":"25","author":"B Clarkson","year":"1970","unstructured":"Clarkson B, Krakoff I, Burchenal J et al (1970) Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer 25(2):279\u2013305","journal-title":"Cancer"},{"issue":"5281","key":"2402_CR78","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/229168a0","volume":"229","author":"D Crowther","year":"1971","unstructured":"Crowther D (1971) L-asparaginase and human malignant disease. Nature 229(5281):168\u2013171","journal-title":"Nature"},{"issue":"5","key":"2402_CR79","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-007-0421-z","volume":"60","author":"S Tardito","year":"2007","unstructured":"Tardito S, Uggeri J, Bozzetti C et al (2007) The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 60(5):751\u2013758","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2402_CR80","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1158\/1535-7163.MCT-08-0589","volume":"7","author":"PL Lorenzi","year":"2008","unstructured":"Lorenzi PL, Llamas J, Gunsior M et al (2008) Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 7(10):3123\u20133128","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2402_CR81","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1535-7163.MCT-06-0447","volume":"5","author":"PL Lorenzi","year":"2006","unstructured":"Lorenzi PL, Reinhold WC, Rudelius M et al (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 5(11):2613\u20132623","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2402_CR82","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2174\/156800911797264725","volume":"11","author":"S Tardito","year":"2011","unstructured":"Tardito S, Chiu M, Uggeri J et al (2011) L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets 11(8):929\u2013943","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"2402_CR83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/bjc.2013.293","volume":"109","author":"B Zhang","year":"2013","unstructured":"Zhang B, Dong LW, Tan YX et al (2013) Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer 109(1):14\u201323","journal-title":"Br J Cancer"},{"issue":"11","key":"2402_CR84","doi-asserted-by":"crossref","first-page":"e13892","DOI":"10.1371\/journal.pone.0013892","volume":"5","author":"C Scotti","year":"2010","unstructured":"Scotti C, Sommi P, Pasquetto MV et al (2010) Cell-cycle inhibition by Helicobacter pylori L-asparaginase. PLoS ONE 5(11):e13892","journal-title":"PLoS ONE"},{"key":"2402_CR85","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bbrc.2008.10.118","volume":"377","author":"D Cappelletti","year":"2008","unstructured":"Cappelletti D, Chiarelli LR, Pasquetto MV, Stivala S, Valentini G, Scotti C (2008) Helicobacter pylori L-asparaginase: a promising chemotherapeutic agent. Biochem Biophys Res Commun 377:1222\u20131226","journal-title":"Biochem Biophys Res Commun"},{"key":"2402_CR86","first-page":"1","volume-title":"Enzymes as drugs","author":"RL Capizzi","year":"1981","unstructured":"Capizzi RL, Cheng Y (1981) Therapy of neoplasia with asparaginase. In: Holcenberg JS, Robert J (eds) Enzymes as drugs. Wiley, New York, pp 1\u201324"},{"key":"2402_CR87","first-page":"185","volume":"39","author":"J Winston","year":"1973","unstructured":"Winston J, Yellin TO (1973) L-asparaginase: a review. Adv Enzymol 39:185\u2013248","journal-title":"Adv Enzymol"},{"issue":"9","key":"2402_CR88","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jama.1967.03130220070012","volume":"202","author":"JM Hill","year":"1967","unstructured":"Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW (1967) L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 202(9):882\u2013888","journal-title":"JAMA"},{"issue":"5","key":"2402_CR89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2141.2003.04703.x","volume":"123","author":"S Okada","year":"2003","unstructured":"Okada S, Hongo T, Yamada S et al (2003) In vitro efficacy of L-asparaginase in childhood acute myeloid leukemia. Br J Haematol 123(5):802\u2013809","journal-title":"Br J Haematol"},{"issue":"8","key":"2402_CR90","first-page":"2879","volume":"96","author":"CM Zwaan","year":"2000","unstructured":"Zwaan CM, Kaspers GJ, Pieters R et al (2000) Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96(8):2879\u20132886","journal-title":"Blood"},{"key":"2402_CR91","first-page":"3641","volume":"118","author":"SA Jun","year":"2011","unstructured":"Jun SA, Sepiashvili L, Kislinger T, Minden MD (2011) Investigating the potential use of L-asparaginase in myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 118:3641","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2402_CR92","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12185-012-1111-0","volume":"96","author":"H Takahashi","year":"2012","unstructured":"Takahashi H, Koh K, Kato M, Kishimoto H, Oguma E, Hanada R (2012) Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to L-asparaginase. Int J Hematol 96(1):136\u2013140","journal-title":"Int J Hematol"},{"issue":"3","key":"2402_CR93","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.critrevonc.2006.07.009","volume":"61","author":"UK Narta","year":"2007","unstructured":"Narta UK, Kanwar SS, Azmi W (2007) Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 61(3):208\u2013221","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"2402_CR94","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1200\/JCO.2002.07.300","volume":"20","author":"Y Perel","year":"2002","unstructured":"Perel Y, Auvrignon A, Leblanc T et al (2002) Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89\/91. Leucamie Aique Myeloide Enfant. J Clin Oncol 20(12):2774\u20132782","journal-title":"J Clin Oncol"},{"issue":"1 Suppl 2","key":"2402_CR95","first-page":"67","volume":"4","author":"G Wrobel","year":"2000","unstructured":"Wrobel G, Dobaczewski G, Kazanowska B et al (2000) Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin\u2019s lymphoma. Report of the Polish Paediatric Leukaemia\/Lymphoma Study Group. Med Wieku Rozwoj 4(1 Suppl 2):67\u201372","journal-title":"Med Wieku Rozwoj"},{"issue":"9","key":"2402_CR96","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2001.19.9.2390","volume":"19","author":"NL Kobrinsky","year":"2001","unstructured":"Kobrinsky NL, Sposto R, Shah NR et al (2001) Outcomes of treatment of children and adolescents with recurrent non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: children\u2019s Cancer Group Study CCG-5912. J Clin Oncol 19(9):2390\u20132396","journal-title":"J Clin Oncol"},{"issue":"1","key":"2402_CR97","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cncr.11480","volume":"98","author":"NR Agrawal","year":"2003","unstructured":"Agrawal NR, Bukowski RM, Rybicki LA, Kurtzberg J, Cohen LJ, Hussein MA (2003) A phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer 98(1):94\u201399","journal-title":"Cancer"},{"issue":"5","key":"2402_CR98","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/ehm.10.51","volume":"3","author":"F Ishida","year":"2010","unstructured":"Ishida F, Kwong YL (2010) Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol 3(5):593\u2013602","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2402_CR99","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B et al (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood 117(6):1834\u20131839","journal-title":"Blood"},{"issue":"5","key":"2402_CR100","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/1042819031000067873","volume":"44","author":"Y Matsumoto","year":"2003","unstructured":"Matsumoto Y, Nomura K, Kanda-Akano Y et al (2003) Successful treatment with Erwinia L-asparaginase for recurrent natural killer\/T cell lymphoma. Leuk Lymphoma 44(5):879\u2013882","journal-title":"Leuk Lymphoma"},{"key":"2402_CR101","first-page":"2191","volume":"42","author":"S Schwartz","year":"1982","unstructured":"Schwartz S, Morgenstern B, Capizzi RL (1982) Schedule dependent synergy and antagonism between high dose cytosine arabinoside and L-asparaginase in the L5178Y murine leukemia. Cancer Res 42:2191","journal-title":"Cancer Res"},{"issue":"3","key":"2402_CR102","first-page":"694","volume":"63","author":"RL Capizzi","year":"1984","unstructured":"Capizzi RL, Poole M, Cooper MR et al (1984) Treatment of poor risk acute leukemia with sequential high dose ARA-C and asparaginase. Blood 63(3):694\u2013700","journal-title":"Blood"},{"issue":"3","key":"2402_CR103","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.1988.6.3.499","volume":"6","author":"RL Capizzi","year":"1988","unstructured":"Capizzi RL, Davis R, Powell B et al (1988) Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia- a cancer and Leukemia group B study. J Clin Oncol 6(3):499\u2013508","journal-title":"J Clin Oncol"},{"issue":"3","key":"2402_CR104","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.1993.11.3.538","volume":"11","author":"RJ Wells","year":"1993","unstructured":"Wells RJ, Woods WG, Lampkin BC et al (1993) Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Children\u2019s Cancer Group. J Clin Oncol 11(3):538\u2013545","journal-title":"J Clin Oncol"},{"key":"2402_CR105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000243725","volume":"122","author":"A Horikoshi","year":"2009","unstructured":"Horikoshi A, Takei K, Iriyama N et al (2009) Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin Lymphoma. Acta Haematol 122:54\u201357","journal-title":"Acta Haematol"},{"key":"2402_CR106","first-page":"4553","volume":"108","author":"H Fujita","year":"2006","unstructured":"Fujita H, Iguchi M, Tachibana T et al (2006) Remission induction treatment for 6 patients of Jehovah\u2019s witnesses with de novo acute leukemia. Blood (ASH Annual Meeting Abstracts). 108:4553","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"issue":"7","key":"2402_CR107","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/pbc.24470","volume":"60","author":"J Buaboonnam","year":"2013","unstructured":"Buaboonnam J, Cao X, Pauley JL et al (2013) Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatr Blood Cancer 60(7):1161\u20131164","journal-title":"Pediatr Blood Cancer"},{"key":"2402_CR108","doi-asserted-by":"crossref","unstructured":"Ahmed T, Holwerda S, Isom S, Lyerly S, Ellis LR, Manuel M, Dralle S, Dmitriy B, Klepin HD, Powell BL, Pardee T (2013) High dose cytarabine, mitoxantrone and L-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) In the elderly. Blood (ASH Annual Meeting Abstracts). 122:2700","DOI":"10.1182\/blood.V122.21.2700.2700"},{"issue":"10","key":"2402_CR109","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712\u20131723","journal-title":"Blood"},{"key":"2402_CR110","unstructured":"Howlader N, Noone AM, Krapcho M et al (2012) SEER Cancer Stat Rev, 1975\u20132010. National Cancer Institute. Bethesda, MD. http:\/\/seer.cancer.gov\/csr\/1975_2010\/ . Based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Accessed 19 Jan 2014"},{"key":"2402_CR111","doi-asserted-by":"crossref","unstructured":"Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV (2013) Inhibition of glutaminase selectively suppresses the growth of primary AML cells with IDH mutations. Exp Hematol. doi: 10.1016\/j.exphem.2013.12.001","DOI":"10.1016\/j.exphem.2013.12.001"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2402-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2402-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T20:36:19Z","timestamp":1746131779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2402-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,11]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2402-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,11]]}}}